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A B S T R A C T   
Breastfeeding plays a major role in the health and wellbeing of mother and infant. However, information on the 
safety of maternal medication during breastfeeding is lacking for most medications. This leads to discontinuation 
of either breastfeeding or maternal therapy, although many medications are likely to be safe. Since human 
lactation studies are costly and challenging, validated non-clinical methods would offer an attractive alternative. 
This review gives an extensive overview of the non-clinical methods (in vitro, in vivo and in silico) to study the 
transfer of maternal medication into the human breast milk, and subsequent neonatal systemic exposure. Several 
in vitro models are available, but model characterization, including quantitative medication transport data across 
the in vitro blood-milk barrier, remains rather limited. Furthermore, animal in vivo models have been used 
successfully in the past. However, these models don’t always mimic human physiology due to species-specific 
differences. Several efforts have been made to predict medication transfer into the milk based on physico-
chemical characteristics. However, the role of transporter proteins and several physiological factors (e.g., 
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variable milk lipid content) are not accounted for by these methods. Physiologically-based pharmacokinetic 
(PBPK) modelling offers a mechanism-oriented strategy with bio-relevance. Recently, lactation PBPK models 
have been reported for some medications, showing at least the feasibility and value of PBPK modelling to predict 
transfer of medication into the human milk. However, reliable data as input for PBPK models is often missing. 
The iterative development of in vitro, animal in vivo and PBPK modelling methods seems to be a promising 
approach. Human in vitro models will deliver essential data on the transepithelial transport of medication, 
whereas the combination of animal in vitro and in vivo methods will deliver information to establish accurate in 
vitro/in vivo extrapolation (IVIVE) algorithms and mechanistic insights. Such a non-clinical platform will be 
developed and thoroughly evaluated by the Innovative Medicines Initiative ConcePTION.   
1. Introduction 
About 50 % of postpartum women need medication, and the evi-
dence on the beneficial effects of breastfeeding is growing [1]. Yet, data 
on the safe use of medication during breastfeeding is lacking for a large 
share of medicines [2]. This knowledge gap often forces women either to 
postpone a much-needed treatment or to discontinue breastfeeding at 
the advice of their healthcare professionals. Strong scientific evidence 
could prevent this unnecessary choice. In fact, many medications are 
likely to be safe as the transfer into the breast milk and/or neonatal 
gastrointestinal absorption are expected to be low for a majority of 
medications. However, clinical lactation studies are costly, 
time-consuming and encounter many practical and ethical limitations. 
Therefore, validated non-clinical research methods could play a crucial 
role in filling the knowledge gap in this field. 
This comprehensive review aims to provide a state-of-the art of non- 
clinical (in vitro, in vivo and in silico) methods to determine transfer of 
medication during lactation. 
2. Methods 
A comprehensive (“non-systematic”) review was performed. Five 
distinct literature searches (see Supplemental Data S1: Search Terms) for 
in vitro models, in vivo animal models, empirical and semi-mechanistic 
models, PBPK models and the effect of maternal conditions on the 
macro-nutrient composition of breast milk were performed searching 
PubMED between September 2019 and December 2019. In addition, 
Embase was searched for the in vitro and in vivo models. Articles were 
excluded if no full text was available or if they were not written in En-
glish. The selection of the articles for the in vitro models and PBPK 
models was performed using Rayyan [3]. 
2.1. In vitro animal models 
Articles regarding in vitro models for the blood milk epithelial bar-
rier, using cell lines or primary cells, were included. 
2.2. In vivo animal models 
Articles on animal models to predict human breast milk exposure or 
human neonatal systemic exposure to maternal medications via breast-
feeding were included. 
2.3. Empirical and semi-mechanistic models (human) 
Articles on empirical or semi-mechanistic models to predict human 
breast milk exposure were included. 
2.4. Physiologically-based pharmacokinetic (PBPK) models 
Articles about PBPK models to predict human breast milk exposure 
or neonatal systemic exposure to maternal medication via breastfeeding 
were included. A review on the use of PBPK modelling regarding 
lactation was conducted previously [4]. However, at that time (in 2003) 
PBPK models were only available for chemical substances or for the 
dairy industry. 
2.5. The effect of maternal conditions on macro-nutrient composition of 
breast milk 
Articles about the effect of maternal conditions on the macro- 
nutrient composition of breast milk were included. 
3. Results 
3.1. In vitro models 
3.1.1. Available in vitro models for the mammary epithelium 
In vitro cell culture models for the mammary epithelium have been 
established to predict medication partitioning into the breast milk, 
based on the assumption that the mammary epithelium (Fig. 1) is the 
main barrier between the systemic (maternal) circulation and the milk. 
Many cell culture models have been established based on human or 
animal mammary epithelial cell cultures, including both primary cells 
and cell lines (Table 1). These cell culture models can be used to study 
not only passive, but also active transport of medication across the blood 
milk barrier. In 2006, the first human model to predict medication 
transfer into the human breast milk was developed by Kimura et al. [6]. 
They used the method from Schmidhauser et al. [7] to obtain 
trypsin-resistant cells, which have the ability to differentiate into the 
lactating state. More recently, Andersson et al. [8] developed a model to 
evaluate the transfer of the neurotoxic amino acid beta-N-methylami-
no-alanine (BMAA) into the breast milk based on its uptake in the human 
mammary MCF-7 cell line. Other mammary cell lines have been used to 
investigate the mammary gland (e.g., PMC42-LA [9]) and in the field of 
breast cancer (e.g., R5, MCF-7, MDA-MB-231-LUC, MCF10A and pri-
mary epithelial cells [10]). In addition, MDCK-II cells transfected with 
human Breast Cancer Resistance Protein (BCRP) have also been used to 
optimize predictions of milk-to-plasma (M/P) ratios for medications 
[11]. Many in vitro models relying on mammary epithelial cells have 
been established based on cells obtained from animal tissue. 
3.1.2. Culture conditions 
Mammary epithelial cells are either obtained via isolation from 
normal breast tissue [25], tumor breast tissue [25] or breast milk [26]. 
Currently, some cell lines can also be obtained from commercial cell 
suppliers. Mammary epithelial cell basal medium (MEBM) (Table S1), 
with addition of several supplements (Table S2), is recommended for the 
growth of HMEC [6]. RPMI 1640, DMEM and DMEM:F12 (50:50) have 
been used for human mammary epithelial cell lines and cells from ani-
mal origin [8]. Basal RPMI 1640 and DMEM:F12 (50:50) are not specific 
for epithelial cells. However, the addition of particular supplements 
makes them suitable for the growth of mammary epithelial cells. 
Different supplements concentrations (Table S2) are recommended by 
the suppliers and in previously mentioned in vitro culture models. The 
choice of supplements and in particular, prolactin, is strategic when 
working with a model of secreting cells. For instance, Freestone et al. [9] 
were able to make a model for the resting, lactating and suckled 
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mammary epithelium, by adding either no, 200  ng/ml, or 800  ng/ml 
prolactin, respectively, to the PMC42-LA cell line. 
3.1.3. Characterization 
Characterization of the in vitro models, especially of the transporters 
(Fig. 2), is important to ensure that the model is applicable to the in vivo 
situation for a specific lactation period and a given compound. An 
overview of the available information regarding transporters has 
recently been given by Ventrella et al. [38]. 
3.1.4. Human in vitro models to predict medication transfer into the breast 
milk 
Two human models have currently been reported for the prediction 
of medication transfer into the breast milk. Kimura et al. [6] used HMEC: 
they were able to obtain a monolayer with a transepithelial electrical 
resistance of 227 +/- 11 Ohm. cm2 after three trypsin treatments, indi-
cating a tight monolayer. They detected beta-casein mRNA, which 
demonstrates that the monolayer is differentiated into the lactating 
state. Shipman et al. [39] showed that beta-casein is only expressed in 
the lactating state. Besides beta-casein, Kimura et al. [6] also detected 
mRNA of organic cation transporter (OCT)1 and OCT3. Interestingly, 
they found that OCT1 mRNA increased, whereas OCT3 mRNA decreased 
with increasing number of trypsin treatments. This observation was 
consistent with the observations of Alcorn et al. [29], who observed that 
OCT1 mRNA levels are higher, while OCT3 mRNA levels are lower in 
vivo in the lactating state compared to the non-lactating state. Kimura 
et al. [6] also investigated the function of OCT and organic anion 
transporter (OAT) with the substrates tetraethylammonium (TEA) and 
p-aminohippurate (PAH), respectively. A clear directionality was 
observed for TEA, indicating that functional OCT is present. However, 
no directionality was observed for PAH. Other transporters that have not 
been investigated in this study, for instance BCRP, play an important 
role in vivo. Therefore, further characterization of this in vitro model is 
required in order to conclude whether this is a good model to evaluate 
medication transfer into the human breast milk. 
Andersson et al. [8] developed a human in vitro model to investigate 
the transfer of D-BMAA and L-BMAA into the human breast milk based 
on their uptake in MCF-7 cells. MCF-7 (Fig. 3) is a cell line derived from a 
metastatic site of an adenocarcinoma, via pleural effusion [40]. MCF7 
expresses estrogen and progesterone receptors and is known to have 
some characteristics of the differentiated mammary epithelium [40]. 
Andersson et al. [8] found that uptake was higher in the differentiated 
model. Furthermore, via inhibition studies with natural amino acids, 
they concluded that several amino acid transporters might be involved 
in the uptake. Additionally, they found some differences in mRNA levels 
of orthologous transporters in the MCF-7 cell line compared to the 
mouse HC11 cell line. Finally, they compared mRNA expression in 
undifferentiated and differentiated HC11 cells and found that mRNA 
increased for some transporters, whereas mRNA decreased for others. 
Besides MCF-7, many other human cell lines have been used to 
investigate the mammary gland. For example, MCF-10A has been used 
commonly as a model to investigate normal breast cells. MCF-10A is an 
immortalized, non-tumorigenic cell line obtained from benign prolifer-
ative breast tissue [41]. MCF-10A does not express estrogen or proges-
terone receptors. Furthermore, no beta-casein or alfa-lactalbumin were 
detected [41]. In addition, Ying Qu et al. [41] questioned whether 
MCF-10A cells are a good model for normal breast cells. They conclude 
that further investigations are required. 
Another frequently used cell line is the MDA-MB-231, which was 
obtained via pleural effusion of a patient with metastatic mammary 
adenocarcinoma [42]. The MDA-MB-231 cell line does not express an 
estrogen or progesterone receptor. Moreover, MDA-MB-231 might not 
be suitable as a model for normal lactating mammary epithelial cells, as 
it is a highly aggressive, invasive and poorly differentiated cell line that 
is mainly used to investigate triple-negative breast cancer. 
Finally, PMC42-LA is an epithelial cell line derived from PMC42, a 
mesenchymal breast carcinoma cell line that has been obtained from a 
pleural effusion. Although PMC42-LA has not been used as frequently as 
the previously mentioned cell lines, it might be a good model for the 
lactating mammary gland. In fact, Freestone et al. [9] were able to 
develop a resting, lactating and suckling in vitro model with this cell line 
by using different concentrations of prolactin. They indicated that the 
capacity to differentiate into a lactating state is a major advantage of this 
cell line compared to many other cell lines. It has also been shown that 
PMC42-LA cells express beta-casein after stimulation with lactation 
hormones [9]. 
Fig. 1. The mammary epithelium consists of lobes, 
containing alveoli and milk ducts. The luminal epithe-
lial cells or acini cells secrete milk into the lumen of the 
alveolus. The surrounding myoepithelial cells contract 
under the stimulation of oxytocin and cause excretion 
of the milk into the ducts. Transport of endogenous 
compounds as well as medication is possible via passive 
or active transport mechanisms. Transcellular transport 
implies crossing of cell membranes, whereas para-
cellular transport occurrs via the confined spaces be-
tween cells.   
Table 1 
Cell culture models of the mammary epithelium.  
Cell culture model Species References 
Primary culture of Human Mammary Epithelial Cells 
(HMEC) 
Human [6] 
Michigan Cancer Foundation-7 (MCF-7) cells Human [8] 
Madin-Darby canine kidney (MDCK) II cells transfected 
with BCRP 
Dog [11] 
HC11 mouse mammary epithelial cells Mouse [8] 
CIT3 mouse mammary epithelial cells Mouse [12,13,14] 
Rat Mammary Epithelial (RME) cells Rat [15] 




BME-UV Immortalized Bovine Mammary Epithelial cells Bovine [20,21,22, 
23] 
Primary goat Mammary Epithelial Cells (pgMECs) Goat [24]  
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3.1.5. Animal in vitro models to predict medication transfer into the breast 
milk 
Prediction of medication transfer into the human breast milk based 
on animal in vitro models might be difficult due to species-specific dif-
ferences (e.g. differences in enzyme and transporter expression and ac-
tivity). However, these in vitro models, in combination with animal in 
vivo models, can play a pivotal role in the in vitro to in vivo extrapolation 
of human in vitro data, as they can generate fundamental and mecha-
nistic knowledge. 
Two main categories can be distinguished: rodent and non-rodent 
models. Among the rodent cell lines: Rat Mammary Epithelial (RME) 
cells are derived from normal mammary glands of 50− 60-day-old virgin 
female Lewis rats [15], while both mouse cell lines (HC11 and CIT3 
cells) are derived from COMMA-1D cells, obtained from mammary tis-
sue of BALB/c mice in the middle of pregnancy. CIT3 are selected for 
resistance to triple trypsinization, while HC11 have been immortalized. 
Both cell lines have been used for active transport studies of medications 
such as nitrofurantoin. 
Among non-rodent cell lines, Bovine Mammary Epithelial cell line 
BME-UV is a clonal cell line established from primary epithelial cells 
from a lactating Holstein cow. This cell line expresses functional markers 
such as microvilli and desmosomes and secreting properties [43], and 
expresses functional organic anion and cation transporters [21,22]. 
Primary goat mammary epithelial cells (pgMECs) derived both from 
mammary tissue of lactating or non-lactating juvenile goats grow in vitro 
for several passages and remain hormone and immune responsive with a 
secreting phenotype (55). Porcine mammary epithelial cells (pMECs) 
can be derived from non-pregnant and non-lactating gilt [17]. These 
primary cells can be maintained in culture for at least 15 passages and 
could represent a good model for studying molecular regulation and 
synthesis of milk (excretion). Alternatively, porcine mammary epithelial 
cells can be obtained from mammary gland after parturition [18]. 
3.2. In vivo animal models 
Different aspects need to be considered when selecting an animal 
species for modelling the lactational transfer of xenobiotics in human 
[44]. The main parameters related to lactation (anatomy of the udder, 
amount of milk production, composition of milk, duration of lactation 
and hormone responsiveness) and medication disposition (transporters 
and enzymes) vary across different animal species. [23,45,54,55, 
46–53]. 
Rodents are usually considered an excellent model in many fields of 
research, but their metabolic and digestive patterns and milk composi-
tion are quite different from humans, with significant differences in 
medication levels reached in blood and the potential lactational transfer 
[56–58]. Indeed, in such species, the general aspects of reproduction 
(age of sexual maturation, hormone sensitivity, reproductive lifespan, 
litter size) are very different when compared to humans [49]. Never-
theless, most studies clarifying the development of mammary cancer 
have been performed in rodents due to their relatively easy manipula-
tion and housing requirements [59,60]. An additional issue with 
working with rodents relates to the body dimension. More specifically, 
rodents allow only for small volume milk sampling limiting the possi-
bility of end point analysis. 
Medication transfer from blood to milk has been extensively studied 
in ruminants [46,61], mainly for human safety reasons, due to their role 
as food producing animals (in particular milk and dairy products). 
Nevertheless, these animals differ significantly from human from an 
anatomical point of view and mainly, in absorption and metabolic ca-
pacity due to their peculiar gastrointestinal physiology. 
Swine offer a generally accepted model in translational medicine 
based on their anatomical and physiological similarities with humans. 
Its use as a model for nutritional physiology, medication testing and 
metabolism has been generally acknowledged [45,52,62–65]. Mam-
mary gland anatomy shows macroscopic differences but, at a molecular 
Fig. 2. Transporter expression in human mammary epithelial cells [6,27,36,37,28–35]. 
Transporters detected either in primary human mammary epithelial cells from commercial suppliers and/or in mammary epithelial cells isolated from milk or breast 
tissue. The arrows indicate the direction of the transport. If no evidence was found for the location of the transporter in the mammary gland, the transporter was 
placed on the expected location based on locations in other tissues (indicated with asterisk). Furthermore, transport protein expression was also found for ABCA7, 
ABCA13, ABCF2, ABCF3, SLC1A4, SLC1A5, SLC3A1, SLC4A2, SLC4A7, SLC5A3, SLC7A1, SLC7A2, SLC9A1, SLC9A3R1, SLC9A3R2, SLC12A1, SLC12A4, SLC12A9, 
SLC15A4, SLC16A2, SLC16A3, SLC20A2, SLC26A2, SLC27A1, SLC27A2, SLC30A1, SLC31A1, SLC35E1, SLC39A14, SLC44A2 & SLC52A2. However, these trans-
porters were not included in the figure since they are currently not known to play an important role in the transport of medication. 
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level, the presence of medication transporters similar to human has been 
reported (See Table 2 from Ventrella et al. [38]). However, the lactation 
duration is shorter, compared to humans. These points have to be 
considered when studying the lactational transfer in the different phases 
of lactation, especially for colostrum composition [55]. The litter size 
allows for an easy milk collection without interfering with the lactation 
process and piglet’s growth; piglets can be analyzed individually and 
have been already utilized as animal model for pediatric PK/PD [66]. In 
recent years, the minipig, and in particular Göttingen Minipigs, has been 
proposed as a more relevant animal model in translational medicine in 
particular for toxicological studies [67,68]. They show, together with all 
the positive characteristics described for domestic swine breeds, a 
reduced growth rate that makes them easier to use. Moreover, since 
some minipig breeds, such as the Göttingen one, are specifically bred 
and produced for experimental purposes, they allow for a much more 
precise genetic and microbiologic standardization, as well as a stan-
dardization of the interactions between animals and the housing 
context, including operators, leading to a significant reduction in the 
number of animals needed for experimental trials [69,70]. The fact that 
Göttingen Minipigs are available in a constant and uniform quality 
worldwide forms the basis of their recognition by regulatory bodies as a 
suitable non-rodent species for toxicology studies. However, data 
regarding qualitative and quantitative composition of the milk, as for 
the domestic pig, are lacking. 
The most relevant papers on animal models of lactational transfer are 
listed in Table 2with indication of the relevant applications and the 
species studied. 
3.3. Empirical and semi-mechanistic models (human) 
Purely empirical models describe the correlation between data, 
while mechanistic models (including PBPK models) also account for the 
underlying physiological processes. Semi-mechanistic models lay be-
tween the empirical models and the mechanistic models. For some as-
pects they rely on physiologically relevant mechanisms, whereas other 
aspects of the model are not physiologically relevant. 
Several attempts have been made to predict the transfer of medica-
tion into human milk using different physicochemical parameters. In 
1959, Rasmussen et al. [71] first assumed pH-dependent diffusion of 
medication, while Notarianni et al. [72] developed an equilibrium 
dialysis model to test the partitioning of medication between freeze 
dried plasma and baby formula powder over a dialysis membrane. Other 
diffusion models have been developed by Atkinson et al. [73] and 
Fleishaker et al. [74]. Meskin and Lien [75] each developed an in silico 
model based on the relation between physicochemical properties (the 
molecular weight, partition coefficient and degree of dissociation) and 
the transfer of medication into the milk. This model was later extended 
with an artificial neural network by Agatonovic-Kustrin [76]. Quanti-
tative structure activity (or property) relationship tools have been 
explored as well [77]. Many others have tried to predict milk transfer 
using similar methods. However, the major limitation with all of these 
methods was that they do not take transporter-mediated processes into 
account. 
In 2011, a semi-mechanistic model was developed by Koshimichi 
et al. [78] (See Fig (1) from Ventrella et al. [38]) to predict medication 
transfer into the milk [78]. Milk secretion and reuptake clearance values 
were estimated by curve fitting against observed milk and plasma 
concentration-time profiles. Next, the fraction of unbound medication in 
Fig. 3. Transporter expression in the MCF-7 cell line [73,74,83,84,75–82]. 
The arrows indicate the direction of the transport. When no evidence was found for the membrane localization of the transporter in the mammary epithelial gland 
cells, the transporter was placed on the expected location based on other tissues. Furthermore, transporter protein expression was also found for ABCA1, ABCA3, 
ABCA7, ABCA11, ABCA12, ABCA13, ABCB5, ABCB6, ABCF2, ABCF3, ABCG1, SLC1A3, SLC1A4, SLC1A5, SLC1A6, SLC3A1, SLC3A2, SLC4A1, SLC4A2, SLC4A7, 
SLC4A8, SLC4A11, SLC5A3, SLC5A6, SLC6A6, SLC6A8, SLC6A15, SLC6A18, SLC7A1, SLC7A2, SLC7A6, SLC7A10, SLC8A3, SLC9A1, SLC9A3R1, SLC9A3R2, SLC9A7, 
SLC10A7,vSLC11A2, SLC12A2, SLC12A4, SLC12A6, SLC12A7, SLC12A9, SLC15A4, SLC16A2, SLC16A4, SLC16Z6, SLC16A12, SLC17A9, SLC19A1, SLC19A2, 
SLC20A1, SLC20A2, SLC22A18, SLC22A23, SLC24A1, SLC26A2, SLC26A3, SLC26A4, SLC26A6, SLC26A8, SLC26A11, SLC27A1, SLC27A2, SLC27A5, SLC27A6, 
SLC30A1, SLC30A9, SLC31A1, SLC34A3, SLC35C2, SLC35E1, SLC35F2, SLC35F3, SLC36A, SLC36A4, SLC38A1, SLC38A2, SLC38A6, SLC39A1, SLC39A3, SLC39A6, 
SLC39A8, SLC39A9, SLC39A10, SLC39A14, SLC41A3, SLC43A2, SLC43A3, SLC44A1, SLC44A2 SLC44A3 & SLC52A2. However, these transporters were not included 
in the figure since they are currently not known to play an important role in the transport of medication. 
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the milk was compared to the fraction of unbound medication in the 
plasma for each medication to determine whether passive diffusion or 
transporter-mediated transfer is the most likely route for medication 
transfer into the human breast milk. For the medications with passive 
diffusion as main pathway, an equation describing the relation between 
the physicochemical properties and the secretion and reuptake clear-
ance values was determined by multiple linear regression. This 
semi-mechanistic model was applied to determine M/P Area Under the 
Curve (AUC) ratios for 71.9 % of the 49 medications, be it within a 3-fold 
error compared to observed values [78]. 
3.4. Physiologically-based pharmacokinetic (PBPK) models 
3.4.1. Physiologically-based pharmacokinetic (PBPK) modelling 
A PBPK model is defined by the European Medicines Agency as “a 
mathematical model that simulates the concentration of a medication 
over time in tissue(s) and blood, by taking into account the rate of 
medication Absorption into the body, Distribution in tissues, Meta-
bolism and Excretion (ADME) on the basis of interplay between physi-
ological, physicochemical and biochemical determinants” [81]. 
PBPK modelling is for instance often applied to predict drug-drug 
interactions and to select an initial dose for pediatrics and first-in- 
human trials [81]. Furthermore, PBPK modelling can be used to pre-
dict transfer of compounds into the breast milk, and subsequent 
neonatal systemic exposure. Research in this field has focused on long 
lasting, bio-accumulative substances (e.g. trichloroethylene) in the field 
of toxicology, and milk transfer in animals providing milk for human 
consumption [4].. More recently, some PBPK models for the prediction 
of transfer of medication into the human breast milk and subsequent 
neonatal systemic exposure, further referred to as lactation PBPK 
models, have been reported (Table 3). Five articles and four conference 
abstracts about lactation PBPK models were retrieved, all within the last 
decade. The reported lactation PBPK models consist of a maternal PBPK 
model coupled to a neonatal PBPK model (Fig. 4) allowing them to 
predict milk transfer and neonatal systemic exposure via breastfeeding. 
The PBPK models for alprazolam, caffeine and tramadol only consist of a 
maternal PBPK model, and can thus only predict milk transfer [82,83]. 
The model for escitalopram is a combination of population pharmaco-
kinetics (popPK) to analyze human breast milk data and PBPK modelling 
to predict infant exposure [84]. These five cases will be discussed in the 
next sections. 
The goal of the lactation PBPK models was to predict the exposure of 
neonates to maternal medication via breastfeeding. In the case of co-
deine, the focus was on differences in exposure due to maternal and 
neonatal differences in CYP2D6 genotype and therefore, morphine for-
mation [86]. The PBPK model for isoniazid also aimed to investigate the 
impact of the polymorphic N-acetyltransferase-2 [89]. No genotype 
specific simulation was performed for escitalopram, rifampicin or 
ethambutol [84,88]. In the case of efavirenz, CYP2B6 polymorphism is 
known to have an impact on the metabolism. Olagunju et al. did not 
perform genotype specific simulations but used reported data for 
Table 2 
Animal models of lactational transfer.  
Main aspect of model discussed Species References 
Animal models in evaluation of the 
safety of medication used during 
lactation 
General aspects not species- 
related 
[44] 
Biomarkers Swine [63,64] 
Colostrum Swine [55] 
Comparative pathology of tumors Mouse [59] 
Digestive system Swine [52] 
Drug development Rodents [65] 
Drug metabolism Rodents, guinea pig, rabbit [47] 
Rodents [56] 









Comparison of human and mouse 
metabolism and reproductive 
lifespan 
Mouse [49] 
Hormonal sensitivity Mouse [60] 
Metabolism Rodents [57] 
Metformin treatment during 
pregnancy 
Swine [62] 
Nutritional aspects Swine [45] 
Non-clinical models of Lactational 
transfer 
Rodents, swine, rabbit, 
sheep, bovine 
[38] 
Pharmacokinetics Swine (minipig) [68] 
Pharmacokinetics and 
pharmacodynamics Swine [66] 
Placentation 
Rodents, guinea pig, 
hamster, rabbit, cat, swine, 
sheep, bovine, horse 
[54] 
Sexual maturation Swine (minipig) [69] 
Toxicology Swine (minipig) [67,70]  
Table 3 
PBPK models for transfer of medication into the human breast milk and subsequent neonatal systemic exposure.  
Compound (indication) Dose Administration route Software References 
Alprazolam (Anxiety disorder) 0.5 mg single dose Oral SimCyp Simulator V16 Abstract 
[82] 









(twice a day administration) 
Oral PK-Sim version 4.0 
MoBi version 2.0 
MATLAB version 7 
MoBi Toolbox for Matlab version 2.0 
[86] 
Efavirenz 
(human immunodeficiency virus) 
400 mg/day or 600 mg/day Intramuscular SimBiology version 5.1 MATLAB 2014b [87] 
Escitalopram (depression, including postpartum) 20 mg/day Oral PK-SIM version 6.3 MATLAB [84] 
Ethambutol (Mycobacterium tuberculosis infection) 25.4 mg/kg Oral MATLAB version 8.0 [88] 










Rifampicin (Mycobacterium tuberculosis infection) 10.9 mg/kg Oral MATLAB version 8.0 [88] 
Tramadol 
(Opioid Analgesic) 
100 mg twice a day Oral SimCYP Simulator V16 Abstract 
[83]  
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pediatric CYP2B6 protein expression in which they induced variability. 
3.4.2. Physiologically-based pharmacokinetic (PBPK) model structure 
Transfer of medication into the human breast milk can be modelled 
in several ways [89]:  
(i) direct transfer of the medication from the blood into the human 
breast milk [91];  
(ii) via uptake into the breast adipose tissue [92]; or  
(iii) a combination of both routes [93]. 
All three approaches have been used for chemical substances. The 
currently available lactation PBPK models for medication all used the 
first approach as described below. Distinct software packages have been 
used to develop the existing models. 
The lactation PBPK models used a whole-body PBPK modelling 
approach. They combine a maternal PBPK model including a breast 
compartment with a neonatal PBPK model. The model for escitalopram 
combines popPK on maternal monitoring data with a neonatal PBPK 
model [84]. Willmann et al. [86] combined four PBPK models: maternal 
PBPK models for codeine and its main active metabolite morphine, and 
neonatal PBPK models for codeine and morphine. 
Different approaches are used to couple the maternal and neonatal 
models. Delaney et al. [84] first analyzed the escitalopram concentra-
tions in the breast milk using popPK. In a next step, they calculated daily 
infant doses using a random combination of the predicted milk escita-
lopram concentrations, milk volumes per feed and frequencies of 
feeding. The calculated daily infant doses are then administered to the 
neonatal PBPK model as a single dose. Willmann et al. [86] used a 
similar approach, but they administered the medication to the neonatal 
PBPK models as multiple doses. They assumed breastfeeding, and thus 
dosing the neonate to take place each 3 h. The doses were calculated 
using the medication concentrations at the time of breastfeeding pre-
dicted by their maternal PBPK model and the breast milk volume. 
Willmann et al. assumed that the absorption of the medication in the 
neonatal model is fast and complete. Furthermore, Olagunju et al. [87] 
calculated the milk concentration by multiplying the M/P ratio with the 
simulated plasma concentration. Subsequently, they calculated the in-
fant dose per breastfeeding session by multiplying the milk volume with 
the milk concentration. 
Garessus et al. [89] used another approach, assuming that the breast 
is completely emptied during each feed. This means that the dose given 
to the neonatal PBPK model is equal to the amount of isoniazid in the 
breast milk at the time of breastfeeding. Dosing of the neonatal model is 
repeated every two hours. Partosch et al. [88] developed a PBPK model 
for ethambutol and a PBPK model for rifampicin. The PBPK models for 
both medications have a similar structure. They included the breast 
compartment in the maternal PBPK model as a reservoir. Excretion into 
the reservoir can be calculated by multiplying the milk volume with the 
milk concentration. The milk concentration is calculated by multiplying 
the plasma concentration with the M/P ratio. Every 4 h, the reservoir is 
opened for 30 min, allowing the medication to transfer to the neonate 
via a milk dose compartment. 
Table 4 gives an overview of the different breastfeeding parameters 
that have been used in the lactation PBPK models. A review aiming to 
Fig. 4. Structure of lactation physiologically-based pharmacokinetic (PBPK) models for medication milk transfer and neonatal exposure of the the breastfeeding 
infant to maternal medication. 
The lactation PBPK models are built with a maternal PBPK model coupled to a neonatal PBPK model with oral administration. 
Table 4 
Breastfeeding parameters used in the lactation PBPK models.  
Infant 
weight 













4 kg 0.1134 l/feed Every 2h N/A [84] 
N/A 13 g/kg/day (d1) 
40 g/kg/day (d2) 
98 g/kg/day (d3) 
140 g/kg/day (d4) 
155 g/kg/day (d5) 
Every 3h N/A [85] 
3.5 kg 0.185 l/kg/day (8d – 4 
months) 
Every 4h 30 min [86] 
N/A Milk volume controlled 
by infant suckling rates 
from literature 
Every 2h N/A [87] 
Abbreviations: SD: standard deviation. 
N. Nauwelaerts et al.                                                                                                                                                                                                                           
Biomedicine & Pharmacotherapy xxx (xxxx) xxx
8
quantify breast milk intake feeding parameters for input into PBPK 
models has recently been published by Yeung et al. [94]. They devel-
oped a nonlinear regression equation on the weight-normalized human 
milk intake. Their results show a maximum intake of 152.6 ml/kg/day 
and a weighted mean feeding frequency of 7.7 feeds/day for exclusively 
breastfed term infants. 
PBPK modelling aims to predict in vivo concentration-time profiles 
based on:  
(i) medication-specific parameters; and  
(ii) physiological parameters. 
The medication-specific data required for the development a PBPK 
model using Simcyp™ (Certara, UK) are summarized in the manuscript 
of Zuhang et al. [95]. Several sources of input data can be used. Delaney 
et al. [84] measured in vivo escitalopram concentrations in breast milk 
from 18 lactating women. They used clearance values from literature, 
which had been determined in vitro. Age-dependent algorithms were 
used to scale the parameters for the neonatal PBPK model. Garessus et al. 
[89] used in vivo data, including an AUC based M/P ratio, obtained from 
literature. AUC based M/P ratios are preferred over single M/P ratios, 
since single M/P ratios vary over time. Some of the in vivo data were 
re-calculated to match their population. Partition coefficients were 
calculated according to an algorithm from Schmitt et al. [96], which was 
also used by Partosch et al. [88]. Both Garessus et al. [89] and Willmann 
et al. [86] used adult clearance values fitted from in vivo data, whereas 
the neonatal clearances were in vivo values obtained from literature. 
Willmann et al. [86] used a range of M/P ratios based on several in vivo 
values reported in literature for both morphine and codeine. Partosch 
et al. [88] used physiological data from literature. In vivo clearance 
values were obtained from literature. For ethambutol, the M/P ratio was 
based on two in vivo data pairs from literature. For rifampicin, an al-
gorithm to estimate the M/P ratio was used, because it was not clear how 
the measurements were done for the sparse available in vivo data [88]. 
Olagunju et al. [87] used an in vivo M/PAUC ratio. They used anthro-
pometric values to predict organ weight and blood flows based on a HIV 
positive cohort of breastfeeding women. For the maternal PBPK model, 
CYP450 abundances were taken from in vivo data. For the neonatal PBPK 
model, data from human liver microsomal samples were used. 
3.4.3. Evaluation of the physiologically-based pharmacokinetic (PBPK) 
models 
PBPK models should be evaluated for their ability to predict in vivo 
pharmacokinetic data. All lactation PBPK models exist as a maternal 
PBPK model coupled to a neonatal PBPK model [84,86–89]. The lacta-
tion PBPK models, except for codeine [86] and escitalopram [84], used a 
separate evaluation for the maternal PBPK models and the neonatal 
PBPK models. The evaluation for the maternal PBPK models was done by 
comparing in vivo plasma concentration profiles from literature with 
predicted plasma concentration profiles. Garessus et al. [89] used 
matched dosing regimens and also compared breast milk concentra-
tions. For escitalopram, medication milk concentration data was 
coupled to a neonatal PBPK model. They first evaluated an adult PBPK 
model against in vivo data and then extrapolated it to neonates and again 
verified this with in vivo data [84]. A bootstrapping technique was used 
by Delaney et al. to evaluate the adult PBPK model, for which they 
pre-specified that the PBPK model would be accepted if the mean plasma 
AUC∞ of the observed data fell within a 95 % confidence interval of the 
mean of the predicted data. Olagunju et al. [87] mentioned an accep-
tance criterion of a 2-fold difference against observed data. 
Different approaches were taken to evaluate the neonatal PBPK 
models. Delaney et al. [84] and Olagunju et al. [87] compared predicted 
neonatal plasma concentrations to in vivo plasma concentrations ob-
tained after exposure via breastfeeding, while Garessus et al. [89] and 
Partosch et al. [88] compared their predicted neonatal plasma concen-
trations with in vivo concentrations after direct oral or intravenous 
dosing of the neonates. Partosch et al. [88] only evaluated the neonatal 
model for rifampicin. Delaney et al. [84] also compared four age groups 
within the first year of life and concluded that the variation was limited 
for escitalopram. Olangunju et al. [87] also predicted the infant expo-
sure for four age groups. Garessus et al. [89] also simulated a worst-case 
scenario by implementing breastfeeding at the time of maximal breast 
milk concentration and using the highest reported individual M/P ratio. 
Willmann et al. [86] simulated a situation comparable to a reported 
fatal case of codeine use during breastfeeding and compared the simu-
lated breast milk and plasma concentrations with the values observed in 
this case. Willmann et al. (132), Garessus et al. [89], and Partosch et al. 
[88] all performed a sensitivity analysis. Willmann et al. (132) investi-
gated the effect of different values for maternal and neonatal morphine 
clearances in the sensitivity analysis. They found that the morphine 
concentration in the neonate was mainly dependent on morphine (as 
codein metabolite) clearance by the neonate and the maternal daily dose 
of codeine. Garessus et al. [89] found that the maternal PBPK model for 
isoniazid for the fast metabolizers was most sensitive to the isoniazid 
clearance, the partition coefficient (Kp) of isoniazid between liver tissue 
and plasma, the dose, the liver organ blood flow and the breast milk 
volume. Partosch et al. [88] found that the maternal model was most 
sensitive to the dose, the clearance and the partition coefficient of the 
liver, whereas the neonatal model was most sensitive to the M/P ratio 
and the bioavailability in the infant. 
One of the assumptions made by the PBPK models is that a general, 
‘mean’ milk composition exists for macronutrients. However, milk 
composition changes, especially during the first days after delivery, but 
also during the time course of each feed, differences related to either 
preterm or term delivery, and the duration of lactation. Milk contains 
carbohydrates, fat, proteins, vitamins and minerals. Delaney et al. [84] 
investigated the intra-feed alteration by comparing escitalopram con-
centrations in foremilk (refers to the milk at the start of a feed, con-
taining less fat) with concentrations in hindmilk (refers to the milk at the 
end of a feed, containing more fat). They concluded that there was a 
significantly higher escitalopram concentration in hindmilk, but the 
impact of the sampling phase for monitoring of the concentration will be 
negligible. In addition, maternal characteristics might have an impact 
on the milk composition. An overview on the effect of several maternal 
conditions on milk composition is presented in Table 5. Overall, the 
differences in macro-nutrient composition are rather limited but can be 
considered during modelling for condition specific settings, e.g., dia-
betes, or when antibiotic concentrations in human milk are collected in 
women with mastitis as an indication for these antibiotics. 
3.4.4. Animal PBPK models 
Lactation PBPK models have also been developed for animals. 
Generally, the animal PBPK models are based on the same concepts as 
the human PBPK models. One of the advantages of animal PBPK models, 
in comparison to human PBPK models, is that the systematic collection 
of in vivo data is easier. However, a limitation is that the knowledge of 
the animal physiology is limited compared to humans. The animal 
lactation PBPK models address different types of research questions. 
Animal PBPK lactation models have been used to address risk assess-
ment questions in food producing animals about residual medication in 
edible tissues and milk for human consumption (e.g., [138–140]). Other 
animal lactation PBPK models, typically for rodents, aim to get insight 
into (human) toxicology (e.g. [141–143],). Animal PBPK lactation 
models have also been used as the basis for the development of human 
lactation PBPK models [91]. In this case, the animal PBPK lactation 
model is first developed and validated for animals and thereafter 
extrapolated to humans by interspecies scaling of the physiological 
factors. 
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Table 5 
Effect of specific maternal conditions (pre-pregnancy existing, pregnancy related or related to logistic settings, environment and lifestyle) on human milk composition 
for macro-nutrients.  
Pre-pregnancy existing maternal conditions Main findings as reported References 
Systematic search on maternal medical conditions 
(diabetes, hypertension and overweight) 
Qualitative, not quantitative reporting. 
Diabetes studies (n = 9): Fat: lower concentration (n = 4); Protein: lower (n = 1); Lactose: lower 
concentration (n = 3); Energy value: higher (n = 1); No differences (n = 2); 
Hypertensive mothers (n = 1): Protein: higher (n = 1); 
Overweight (n = 4): Fat: higher (n = 2); Energy content: higher (n = 2); No differences (n = 2) 
[97] 
Overweight or obesity compared to term normal weight, 
colostrum 
Fat: increased in colostrum (craematocrit, 5.6 to 3.3 %); Protein: higher (4.2 to 3.9 g/dl) in term 
colostrum, no differences from 2nd week onwards; Carbohydrates: similar or higher (3.2 to 1.9 mmol/l); 
Caloric content: higher (688 to 538 kcal/l) 
[98,99] 
Pre-pregnancy Body Mass Index (BMI), colostrum 
composition 
Protein: positively related to pre-pregnancy BMI (normal weight vs obese, 4.23 vs 3.9 g/dl); Energy 
content: not affected; Macro-nutrient: not affected 
[100] 
Body Mass Index Carbohydrate: 7.0 g/dl; Protein: 1.1 g/dl (IQR 1.1− 1.2); Fat: 3.5 g/dl (3− 4.1); Energy content: 66 
(62− 72.5) kcal/dl. Maternal BMI positively related to lipid (r = 0.37) and energy (r = 0.39) milk content 
(p < 0.05) 
[101] 
Diet and Body Mass Index Not diet, but maternal body composition (BMI) associated with human milk composition. Milk fat content 
related (r = 0.33) to BMI, and between protein content and body composition (% fat mass (r = 0.60), fat- 
free mass/kg (r = 0.63; p = 0.001), and muscle mass (r = 0.47; p = 0.027). However, postnatal age is a 
relevant driver (1st, 3th and 6th month) 
[102] 
Fat mass Protein: Higher with maternal % fat mass (difference 0.16, SD 0.07 g/l, p = 0.028). Limited changes over 
the first year of lactation as the mean concentrations were 12.94, 11.7, 10.83, 12.83 and 11.96 g/l in the 
2nd, 5th, 9th and 12th month of lactation. 
[103] 
After bariatric surgery Fat: higher on day 4 after delivery 3.0 ± 0.7 versus 2.2 ± 0.9 g/100 ml; Carbohydrate: slightly higher on 
day 4 and 6.6 ± 0.6 versus 6.3 ± 0.4 g/100 ml; Energy: higher on day 4 61.0 ± 7.2 versus 51.7 ± 9 kcal/ 
100 ml. The nutritional value of breast milk after bariatric surgery appears to be at least as high as in non- 
surgical controls 
[104] 
Celiac disease Protein: decrease during first 3 months; n-6 long chain polyunsaturated fatty acids: decrease during the 
first 3 months of lactation; No relevant effect of celiac disease 
[105] 
Human immunodeficiency virus (HIV) infection Fat: higher (4.42 to 3.49 g/100 g); Protein: HIV-infected women contained higher (1.95 to 1.78 g/100 g); 
Carbohydrate: lower (5.37–6.67 g/100 g); Zinc: lower (5.26–5.78 mg/l) Copper: higher (0.64 to 0.56 mg/ 
l) 
[106] 
Lactational mastitis Lactational mastitis (n = 15) to controls (n = 15). Fat: lower (2.1 vs 3.6 g/dl); Protein: not different (1.8 vs 
1.4 g/dl); Carbohydrates: lower (5.1–6.9 g/dl); Energy: lower (54–67 kcal/dl) 
[107] 
Hemodialysis Case report; Creatinine: different; Urea: different; Sodium: different; Chloride: different; Phosphate: 
different; Otherwise high similarity to control breast milk 
[108] 
Cystic fibrosis Milk secreted by 2 women with CF appears to be physiologically normal, including sodium. Third case 
report confirms these finding 
[109,110] 
Homogenous familial hypo-betalipoproteinemia Lipid: lower, with another profile, based on 2 cases [111,112] 
Age, < or ≥ 35 years Fat: higher in colostrum of mothers with advanced age elevated; Carbohydrate: higher in mature milk of 
mothers with advanced age; positive correlation between maternal age and carbohydrate content in 
mature milk 
[113] 
Lactating adolescents Fat: unaffected (6th week: 41.6 ± 3.3; 10th week: 36.2 ± 3.4; 14th week: 31.5 ± 9.0 g/day); Protein: 
significant reduction (p < 0.05) during the postpartum weeks studied (6th week: 16.6 ± 1.1; 10th week 
13.7 ± 1.0; 14th week: 12.3 ± 1.1 g/day); Lactose: unaffected (6th week: 60.2 ± 1.9; 10th week: 60.4 ± 2.6; 
14th week: 65.1 ± 4.0 g/day) 
[114]  
Maternal pregnancy-related conditions Main findings as reported References 
Preterm delivery Systematic review and meta-analysis, 13 papers. Fat: (r2 = 0.94); Protein: decreases massively and significantly 
(r2 = 0.93) from day 1 to 3 to reaches 50% of the initial value at week 10− 12; Lactose: (r2 = 0.80); Energy: 
(r2 = 0.81) (linear trends) 
[115] 
Nutrition and preterm delivery 367 milk samples, 81 mothers after preterm delivery. Lipids: 3.4(1.3− 6.4) g/100 ml; Protein: 1.3(0.1− 3.1) g/100 ml. 
Carbohydrates: 6.8(4.4− 7.3) g/100 ml; There was a (weak) relationship between mothers’ carbohydrates intake 
(r = 0.164; p < 0.01) and milk composition [lipids r2 = 0.087; protein 0.299; calories 0.101]. Postnatal age was the 
most relevant covariate for protein (r=-0.505) and carbohydrates (r = 0.202) 
[116] 
Systematic review on human milk composition 
after preterm delivery 
Based on 24 studies, comparing lactation week 1 to lactations weeks 2− 8, and in mean values. Protein: 1.9 to 1.27 g/ 
100 ml; Lipid: 2.59–3.46 g/100 ml; Carbohydrate: 6.55 to 6.15 g/100 ml; Energy content: 57.11–65.6 kcal/100 ml 
[117] 
Preterm delivery Fat: 1.9 ± 1.8 g/dl to 3.4 ± 2.1 g/dl; Protein: decline from 4.1 ± 2.1 g/dl to 2.2 ± 0.6 g/dl; Lactose: increase from 
2.2 ± 0.7 g/dl to 3.0 ± 0.9 g/dl; Energy: increase from 42.3 ± 18.8 Kcal/dl to 51.9 ± 21.5 Kcal/dl (all, day 3–28) 
[118] 
Preterm to term delivery No significant differences between preterm and full-term milk (p > 0.05). The lowest creamatocrit, calories and fat 
concentration was in morning preterm milk (4.86 %, 663.8 kcal/l and 33.6 g/l, respectively). The highest milk 
parameters were observed in the night full term samples (9.6 %, 919.7 kcal/l, and 60.7 g/l, respectively) 
[119] 
Preterm to term delivery Fat: higher (p < 0.05) in preterm milk (2.9–6.8 and 2.9–4.9 g/dl); Protein: both preterm (2.6 to 1.9 g/dl) and term 
milk (2.2 to 1.1 g/dl) decreased with lactation duration, with higher values in extremely preterm (<28 weeks) than in 
moderately (pre)term milk (p < 0.0001); Carbohydrate: higher (p < 0.05) in preterm milk (6.3–8.5 and 5–7.4 g/dl, 
week 1–8, preterm versus term); Energy: higher (p < 0.05) in preterm milk 
[120] 
Preterm (<33, or 33− 36 weeks) to term 
delivery 
Human milk samples were collected from 86 mothers on days 3, 7, 14 and 28 of lactation. Day 3–28, <33, 33− 36, or 
term: Fat: 1.2, 1.3 and 2–3.1, 3.6 and 3.11 g/dl Lower in preterm samples, post-delivery increase; Protein: (g/dl): 4.1, 
4 and 1.9 to 1.6, 0.9 and 1.1 Higher in preterm samples, post-delivery decrease; Lactose: (g/dl): 3.8, 4.74 and 5.18–7, 
7.5 and 7.7 Lower in preterm samples, post-deliver increase 
[121] 
Very preterm (VP) to preterm (P) to term (T) 
delivery 
Fat: colostrum, transitional and mature milk was 4.05, 4.76 and 4.67 (VP), 2.58, 3.75, 2.98 (P) and 2.6, 3.11, 3.06 g/ 
100 ml (T). Creamatocrit: 6.3, 7.1, 7 (VP), 4.2, 5.8, 5 (P) and 4, 5.1, 5 (T) % 
[122] 
Small-for-gestational-age to appropriate infant Crematocrite: similar on day 3 (7.8 to 6.8), 7 (11.9 to 9.7) and 14 (9.6–10.3) % [123] 
Pre-eclampsia Macro-nutrient: no quantitative differences; Free fatty acids: qualitative differences [124] 
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4. Discussion 
4.1. In vitro human and animal models 
Several in vitro models using mammary epithelial cells are available 
to investigate the transfer of medications into breast milk, while other 
epithelial cell lines derived from different tissue (intestine, kidney) can 
be used as reference models for the epithelial cell barrier (Table 6). The 
in vitro model needs to be ‘biorelevant’, i.e., representative for the in vivo 
human physiology. Therefore, HMECs are expected to be a good model 
for the blood milk epithelial barrier. HMECs have previously been used 
by Kimura et al. [6], but further characterization is required before 
concluding whether this is an adequate model for medication crossing 
over the mammary epithelium. 
Several supplements should be added to the basal media. Some types 
of supplements, such as glutamine [24,144,145] and foetal bovine 
serum [8,13,146,14,16–20,23,24], are used in most cell cultures to 
ensure proper energy metabolism and appropriate growth. Bovine pi-
tuitary extract is commonly used in the culture of HMECs when working 
serum-free [6,13,145–149]. The Guidance Document on Good in vitro 
Method Practices guideline [150] recommends to work serum-free 
where possible. The guideline further advises to minimize the use of 
antibiotics. Hormones, such as insulin [6,8,146,148,149,151,13–17,23, 
24,145] and hydrocortisone [6,13,146,148,149,152,15–19,23,24,145], 
are added to stimulate correct proliferation and differentiation in 
epithelial cells. Furthermore, the specific Epidermal Growth Factor 
(EGF) is almost always added to stimulate growth [6,8,148,149,153, 
13–15,17,16–19,23,146]. In order to develop a differentiated model of 
the lactating mammary epithelium, EGF is removed and prolactin is 
added to the medium. Several other supplements could be added to cell 
culture models but did not seem to be critical. 
Human cell lines are an alternative for HMEC. The advantage is that 
cell lines are generally easier to culture and have a longer life span. The 
cell lines should be a surrogate for the in vivo mammary barrier physi-
ology. Therefore, MCF-7, MCF-10A or PMC42-LA could be good options. 
In addition, animal cells and/or cell lines can be explored. This might 
especially be useful to obtain mechanistic insights and scaling infor-
mation for in vitro to in vivo extrapolation (IVIVE) and the development 
of PBPK models. Even if rodent mammary epithelial cells are the most 
widely studied and provided many biological insights, it is evident that 
the rodent mammary gland is not fully representative of the human 
setting. Therefore, other in vitro animal models have been explored, 
including bovine, goat and porcine. From a physiological, anatomical 
and metabolic point of view, ruminants provide a model very far from 
humans, whereas the porcine species is recognized as an excellent model 
for translational purposes [155–158]. Among the different in vitro 
models of mammary epithelial cells available, primary cell cultures offer 
the opportunity to study the factors that regulate physiologically rele-
vant development of normal mammary epithelial cells under defined 
conditions. 
Overall, it can be concluded that several in vitro models are available 
which allow for determination of the partitioning of medications over 
the epithelial blood milk barrier. However, characterization of the cell 
culture models for this application remains rather limited. 
4.2. In vivo animal models 
Medication excretion in milk during lactation can be successfully 
investigated utilizing in vivo studies in lactating animals [38,44]. The 
principal benefits of in vivo animal studies in this field are:  
(i) the possibility to clarify also the mechanistic aspect of milk/blood 
barrier;  
(ii) the possibility to evaluate the influence of various parameters on 
the rate of medication excretion in milk (milk composition, 
timing of milking, drug-drug interaction, and different models of 
excretion even at molecular level); and  
(iii) the possibility to evaluate the effects of excreted medication or 
metabolites on the offspring. 
The combination of the animal model with an in vitro-based pre-
liminary screening phase may reduce the number of animals needed and 
Logistic settings, environment and lifestyle Main findings as reported References 
Donor milk, compared to literature Fat: 3.22, SD 1.00; Protein: Banked donor milk mean values (g/100 ml) were found to be 1.16, SD 0.25; Lactose: 7.80, 
SD 0.88; Energy: 65+/-11 kcal/d; Macronutrient: differs from the values reported in the literature for mature human 
milk 
[125] 
Manually expressed milk Paired study in 21 women, 48− 72 h after delivery; Fat: higher (2.3 to 1.84 g/100 ml) in breastmilk expressed 
manually 
[126] 
Feeding over 24 h time interval Fat: significantly differed over 24 h (p = 0.01); Protein: remained the same, the mean 24 -h total protein, whey, and 
casein inversely (pP0 < .01) related to the number of feeds per day. Pre-feed samples differ from post-feed samples. 
Lactose: remained the same, positively (p = 0.03) related to the number of feeds per day 
[127] 
Across 9 different countries, protein content 
in mature human milk 
Total protein: steady decline from 30 to 151 days of lactation, significantly higher in the second month of lactation 
compared with the following 4 months (y = 23.251x-0.1554 (g/l), x = lactation days); True protein: steady decline 
from 30 to 151 days of lactation, significantly higher in the second month of lactation compared with the following 4 
months (y = 18.86x-0.1705 (g/l), x = lactation days); Individual amino acid: steady decline from 30 to 151 days of 
lactation, significantly higher in the second month of lactation compared with the following 4 months. There is a high 
level of consistency in the protein content and amino acid composition of human milk across geographic locations, 
with Chile as an outlier. Stage of lactation explained 22.9 and 16.9 % of the variation in total protein and total amino 
acid concentration 
[128] 
High-altitude adapted population (Tibet) Fat: averaged 5.2 ± 2.0 g/100 ml; Protein: 1.26 ± 0.35 g/100 ml; Total sugar: 7.37 ± 0.49 g/100 ml; Energy density: 
81.4 ± 17.4 kcal/100 ml. No associations between altitude of residence and milk composition 
[129] 
Vegetarian and non-vegetarian diet Fat: no differences; Precursors of arachidonic acid: higher (n = 12) [130] 
Vegetarian versus omnivore diet Fat: lower in women with a vegan (3.0), compared to vegetarian (4.0) or omnivore (4.0) g/dl diet; Qualitative 
differences in (un)saturated fats 
[131] 
Diet Macronutrient: (fat, protein, and lactose) not affected by maternal diet; Fatty acid profile: affected by maternal diet [132] 
Active nicotine smoking Fat: (3.47 vs. 4.34 g/dl) lower in smokers; Lipid: lower (-26%, 31.1 vs 42.4 mg/ml); Protein: lower (-12%, 13.1 vs 
14.9 mg/ml) 
Nicotine: 3-fold higher for smoking women than in maternal plasma 
[133,134] 
Passive nicotine smoking Lipids: affected (-28 % and -35 % in triglycerides at baseline and at 4 months) [135] 
Acute fasting (24− 25 h) Immediately after fast: Protein: increase; Lactose: decrease; Sodium: increase; Calcium: increase; Phosphorus: 
decrease; Triglycerides: unchanged 
24 h after fast, parameters are no longer significantly different from baseline except for mean protein levels and 
lactose. No relevant changes in macronutrients 
[136] 
Chronic fasting (repetitive model, Ramadan) Macronutrient: no significant effect (morning samples); Zinc: decreased; Magnesium: decreased; Potassium: decreased [137]  
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mitigate ethical concerns. 
4.3. Empirical and semi-mechanistic models (human) 
Koshimichi et al. [78] showed that semi-mechanistic models can be 
used to predict the transfer of compounds into human breast milk. The 
main advantage of this semi-mechanistic model over other reported 
methods to predict medication transfer into the human milk is that the 
model of Koshimichi did consider that milk and plasma 
concentration-time profiles do not change in parallel. Koshimichi et al. 
found that secretion and reuptake values are similar for most com-
pounds, suggesting mainly passive diffusion. However, for some com-
pounds, transporter-mediated secretion or reuptake plays an important 
role. The model developed by Koshimichi et al. thus allows to distin-
guish between compounds that undergo passive diffusion into the milk 
and compounds that undergo transporter-mediated partitioning. How-
ever, with a 3-fold error tolerance, there is still room for improvement. 
The main advantage of PBPK models over empirical and semi- 
mechanistic models is that PBPK models are based on the underlying 
in vivo physiological mechanisms. This will allow inclusion of 
transporter-mediated milk secretion or reuptake in medication-specific 
PBPK models. Therefore, it can be expected that more reliable pre-
dictions can be obtained with PBPK modelling. 
4.4. Physiologically-based pharmacokinetic (PBPK) models 
4.4.1. Human lactation PBPK models 
Recently, some PBPK models became available for the prediction of 
breast milk exposure, and neonatal systemic exposure to maternal 
medication via breastfeeding [84,86–89]. The available models, despite 
some limitations, show the value of PBPK modelling in this research 
field. The models illustrate that PBPK modelling can be used to handle 
several research questions, including breast milk exposure and neonatal 
systemic exposure via breastfeeding. A major advantage of PBPK 
modelling is that non-clinical data can be used to predict in vivo PK 
behavior of medication. This is especially important, given that clinical 
studies in a vulnerable population like lactating women and their neo-
nates are time-consuming, and give rise to ethical and practical issues. 
One of the main challenges is that there is currently no breast milk 
compartment available in either Simcyp™ (Certara, UK) or PK-Sim® 
(Open Systems Pharmacology). Another important challenge is the need 
for high quality input data. The knowledge regarding the physiology of 
lactating women and nursing neonates is growing, but further research 
in this field is required to optimize existing, and develop new PBPK 
models. Furthermore, an immense information gap exists regarding the 
excretion of medication into the human breast milk and subsequent 
neonatal gastrointestinal absorption. However, information will become 
available within the course of ConcePTION. ConcePTION is a project 
funded by the Innovative Medicines Initiative, which aims to reduce 
uncertainty about the use of medication during pregnancy and lactation 
[159]. The quality of the input data is critical for the quality of the final 
PBPK model. The lack of robust data is illustrated by the hurdles that 
some of the articles had for obtaining the M/P ratio for the respective 
model medication. Furthermore, AUC-based M/P ratios, which are more 
reliable than single M/P ratios, are not always available. In the absence 
of (high quality) clinical data, some of the M/P ratios were estimated 
Table 6 
Overview of selected epithelial cell culture models that may be useful when mimicking the blood-milk barrier..  
In vitro 
model 
Species Tissue Cell type Characteristics References 
HMECs Human Breast Primary epithelial cells, normal Differentiation into lactating state after stimulation with 
lactogenic hormones 
Used to investigate active transport (e.g. TEA or PAH) 
[6] 
MCF-7 Human Breast Cancer epithelial cell line Several characteristics of differentiated mammary epithelium 
retained (e.g. formation of domes) 
Estrogen and progesterone receptor 
Used to investigate active transport (e.g. BMAA) 
[8,40] 
MCF-10A Human Breast Non-tumorigenic epithelial cell line Suitability as a model for normal breast cells questioned 




Human Breast Cancer epithelial cell line Highly aggressive, invasive and poorly differentiated 
Not suitable as a model for normal breast cells 
[42] 
PMC42-LA Human Breast Cancer epithelial cell line Differentiation into lactating state after stimulation with 
lactogenic hormones 
Suitable as a model for normal breast cells 
[9] 
Caco-2 Human Colon Cancer epithelial cell line Frequently used as a model to determine permeability of 
medication 
[154] 
MDCK II Dog Kidney Epithelial-like cell line, normal Transfection with BCRP possible [11] 
IPEC-J2 Porcine Jejunum Primary epithelial cell Suitable as a model of normal epithelial barrier to determine 
permeability of medication 
[80] 
HC11 Mouse Breast Immortalized and non-transformed epithelial cell line 
derived from Comma 1D cells (normal mammary cell line) 
Differentiation into lactating state after stimulation with 
lactogenic hormones 
Used to investigate active transport (e.g. mitoxantrone) 
[8] 
CIT3 Mouse Breast Epithelial cell line derived from Comma 1D cells (normal 
mammary cell line) via triple trypsinization 
Differentiation into lactating state after stimulation with 
lactogenic hormones 
Used to investigate active transport (e.g. nitrofurantoin) 
[12,13,14] 
RME Rat Breast Primary epithelial cells, normal Differentiation into lactating state after stimulation with 
lactogenic hormones 
[15] 




BME-UV Bovine Breast Immortalized epithelial cell line Differentiation into lactating state after stimulation with 
lactogenic hormones 
Used to investigate active transport (e.g. [14C]- 
tetraethylammonium bromide and [3 H]-estrone sulphate) 
[20,21,22, 
23] 
pgMECs Goat Breast Primary epithelial cells, normal Differentiation into lactating state after stimulation with 
lactogenic hormones 
[24] 
Abbreviations: HMECs: human mammary epithelial cells; TEA: tetraethylammonium; PAH: p-aminohippurate; MCF-7: Michigan Cancer Foundation 7; BMAA: beta-N- 
methylamino-alanine; caco-2: cancer colon 2; MDCK II: Madin-Darby canine kidney II; BCRP: breast cancer resistance protein; HC11: HC11 mouse mammary epithelial 
cells; CIT3: CIT3 mouse mammary epithelial cells; RME: rat mammary epithelial cells; pgMECs: primary goat mammary epithelial cells. 
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using the Schmitt et al. algorithm [96]. However, a major limitation of 
this algorithm is that it does not account for transporter involvement. 
The guideline on the reporting of PBPK modelling and simulation of 
European Medicines Agency [81] and the Physiologically Based Phar-
macokinetic Analyses – Format and Content Guidance for Industry from 
Food and Drug Administration [160] should be followed. This will 
assure the quality of the developed PBPK models and also their suit-
ability for registration purposes. Multiple aspects are important to 
consider during the development of the PBPK models, as indicated by 
the available models. For example, some of the lactation PBPK models 
performed a genotype-specific simulation, whereas others did not take 
genotype into account. However, the example of codeine shows the 
importance of genotype specific simulation for certain medications. 
Codeine has long been considered safe until the death of a neonate was 
attributed to it [161]. This event has led to caution using codeine while 
breastfeeding, although it has to be noted that there is some doubt in the 
literature about whether neonates can develop opioid toxicity from 
breastfeeding [162]. The PBPK model of Willmann et al. [86] suggests 
that a combination of worst case factors, including the genotype of 
mother and infant, could have led to the death of the neonate. 
Neglecting the genotype might lead to the conclusion that a medication 
is safe, while this is not the case for all genotypes. Especially since the 
prevalence of polymorphisms in the infant are not disconnected from the 
mother and the limited metabolic (glucuronidation) capacity of 
neonates. 
Another important aspect is how the transfer of medication into the 
breast milk and breastfeeding of the neonate is implemented in the PBPK 
models. The transfer of medication has been modelled as either direct 
transfer from the blood to the breast milk or as transfer via uptake into 
the breast tissue. Furthermore, there was some variation in the param-
eters that have been used to implement breastfeeding in the PBPK 
models (e.g., duration of breastfeeding, frequency of breastfeeding and 
daily milk consumption). Recently, Yeung et al. quantified breast milk 
intake feeding parameters in infants for input into PBPK models [94]. 
Even though literature shows that the milk composition is relatively 
constant in several maternal conditions, possible effects of the specific 
disease population on the milk composition should be kept in mind. 
Also, Delaney et al. [84] showed that there was a significant difference 
in medication concentrations between foremilk and hindmilk. The 
composition of the milk might thus play a role in the exposure of infants 
to maternal medication via breastfeeding. It is therefore important to 
understand the factors that influence the milk composition. Delaney 
et al. also investigated the variation between different age groups within 
the first year of life. Although the conclusion was that the variation is 
limited between the age groups for escitalopram, the age might have an 
important effect on the exposure to some medications, as it has been 
shown that clearance is dependent on the age of the neonate [163]. 
Olugunja et al. [87] did take this into account by doing separate pre-
dictions for different age groups. All of these factors can also be used to 
simulate worst-case scenarios. 
PBPK models should be evaluated for their ability to predict the in 
vivo exposure. Delaney et al. [84] and Olagunju et al. [87] were the only 
ones to use pre-specified acceptance criteria. There is no consensus on 
which criteria should be used for acceptance of PBPK models as this 
depends on the purpose, but a 2-fold deviation is often used as default in 
literature. The guideline for PBPK models [81] indicates that a com-
parison of the simulated and observed individual plasma 
concentration-time profiles should be presented as plots and tabulations. 
Matched predicted and in vivo data should be used. 
4.4.2. Animal lactation PBPK models 
Besides human lactation PBPK models, several animal PBPK lacta-
tion models have been reported. Typically, these animal lactation PBPK 
models have been developed for dairy animals or rodents. The goal can 
either be to gain information for the modelled animal species or to 
translate the information to humans. Translation of animal PBPK 
information to humans is especially valuable in case in vivo human data 
are lacking. However, species differences, for example in transporter 
expression, complicate the direct translation of data from animal PBPK 
models to humans. Nevertheless, lessons learned during IVIVE-PBPK 
modelling while relying on animal in vitro data for the blood-milk bar-
rier, followed by comparison with corresponding in vivo data will be 
instrumental for improving human PBPK lactation models. A similar 
approach was taken by Parrott et al. to predict oseltamivir disposition in 
neonates and infants [164]. At least initial estimates for scaling factors 
for the IVIVE step can be derived in this way. Simcyp™ v18 allows to 
build PBPK models in the rat, dog, mouse and monkey, while PK-Sim® 
also supports mini-pig. 
5. Conclusion 
The iterative development of a non-clinical platform should allow to 
predict breast milk transfer, and subsequent neonatal systemic exposure 
to maternal medication via breastfeeding. First, a human-relevant in 
vitro cell culture model, representative for the in vivo physiology should 
be developed and characterized. Transepithelial permeability data, 
generated with the in vitro model can then be subjected to IVIVE fol-
lowed by PBPK modelling. Essential scaling information for IVIVE can be 
generated by the paired interpretation of animal in vitro and in vivo 
models. Furthermore, the in vivo animal models can deliver key mech-
anistic insights to support the physiological plausibility of the PBPK 
models. The non-clinical tools should be evaluated for their predictive 
performance using diverse model compounds for which in vivo data are 
available. The iterative development of several non-clinical tools will 
ultimately lead to robust predictions of breast milk transfer and neonatal 
systemic exposure to maternal medication, for which data are currently 
lacking, ultimately driving a paradigm shift in the domain of pharma-
cotherapy during lactation. 
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animal model for human pathologies: a proteomics perspective, Proteomics Clin. 
Appl. 8 (2014) 715–731, https://doi.org/10.1002/prca.201300099. 
[64] D. Ventrella, F. Dondi, F. Barone, F. Serafini, A. Elmi, M. Giunti, N. Romagnoli, 
M. Forni, M.L. Bacci, The biomedical piglet: establishing reference intervals for 
haematology and clinical chemistry parameters of two age groups with and 
without iron supplementation, BMC Vet. Res. 13 (2017) 1–8, https://doi.org/ 
10.1186/s12917-017-0946-2. 
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